ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Vasculitis

Will You Buy In on the Next Biosimilar?

The FDA has deferred a scheduled meeting about Remsima, the infliximab biosimilar already approved in Europe and still awaiting judgment in the US. But approval of the first US biosimilar (a version of the cancer drug filgrastim) prompted warnings from two organizations concerned with rheumatic disease, including the ACR. Are you ready the next challenge to your clinical judgment?

Vasculitis

(©PavelLPhotoVideo/Shutterstock.com)

Tocilizumab in its subcutaneous form is the first-ever drug designated for giant cell arteritis which affects 230,000 people in the U.S

Blood vessels (©Vlue/Shutterstock.com)

Mayo Clinic’s Dr. Eric Matteson and Dr. Sharon Chung of UCSF provide an update on advances in new treatments for vasculitis.

(©AlilaMedicalMedia/Shutterstock.com)

Two new studies find that abatacept plus prednisone improves duration of remission for giant cell arteritis patients, but not for Takayasu’s arteritis patients.

(Gastrointestinal tract. © Tefi/Shutterstock.com)

Gastrointestinal involvement is known to be associated with primary vasculitis. But in some cases, it may be IBD with secondary vasculitis, this review shows.

©bleakstar/Shuttersstock.com

The European League Against Rheumatism has updated its 2009 recommendations for the management of antineutrophil cytoplasmic antibody-associated vasculitis.

Top reports chosen by Annals of Internal Medicine include several on biologics for rheumatoid arthritis and psoriatic arthritis, and mechanisms for lupus and scleroderma.

A systematic review finds the technique highly sensitive and specific in diagnosing giant cell arteritis, especially useful when biopsy results are equivocal.

Pages

Subscribe to Vasculitis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.